Autoimmune Neuromuscular and Nerve Disorders Drug Development Summit

Memo

Over the past year, the Myasthenia Gravis landscape has transformed from a once-sparse market into a highly competitive, multi-billion-dollar arena, driven by breakthroughs in FcRn inhibition, complement targeting and B-cell modulation. This surge has sparked growing interest in applying these approaches to adjacent neuromuscular and peripheral nerve disorders, yet critical gaps in disease biology, patient stratification and biomarker validation continue to limit clinical success. The Autoimmune Neuromuscular and Nerve Disorders Drug Development Summit is the first industry-led forum dedicated to transforming the MG, CIDP, GBS and MMN treatment landscapes, bringing together biopharma leaders to tackle the mechanistic and translational challenges shaping this rapidly evolving space. This meeting is uniquely positioned to address these challenges. Unlike pathway-specific or clinician-led events, it is indication-focused, mechanism-driven and tailored exclusively to drug developers, enabling deeper discussion on pathophysiology, differentiation and translational strategy. As competition intensifies and more companies enter the space, success will depend on how well you understand, and exploit, the underlying biology. Join your peers to de-risk development, identify new opportunities and gain a competitive edge in one of the fastest-moving areas of immunology and neurology. URLs:Tickets: https://go.evvnt.com/3581832-1?pid=5569Brochure: https://go.evvnt.com/3581832-3?pid=5569 Prices:Industry Pricing - Conference + Workshop Day: USD 4397.00,Industry Pricing - Conference Only: USD 3099.00,Academic Pricing - Conference + Workshop Day: USD 3797.00,Academic Pricing - Conference Only: USD 2699.00,Vendor Pricing - Conference + Workshop Day: USD 5297.00,Vendor Pricing - Conference Only: USD 3799.00 Speakers: Jessica Van Baaren, Senior Scientist and Project Manager, Neuromuscular Translational Biology, UCB, Karen Lynch, Global Senior Director, Medical, Sanofi, Tarek Samad, Senior Vice President and Global Head, Research, Lundbeck, Sanjay Rakhade, Executive Medical Director, Clinical Development, Alexion Pharmaceuticals, Julian Chandler, Associate Director, Alexion Pharmaceuticals, Beatrix Bartok, Vice President, Clinical Development, Biogen, Tony Shock, Director, UCB, Martin Kolev, Director, Complement Science, Apellis Pharmaceuticals, Lien Dejager, Head, Translational Science, argenx, Bianca Balbino, Senior Clinical Scientist, argenx, Salma Merchant, Biology Research Scientist, Alnylam Pharmaceuticals, David Ngai, Scientist, Biology, Alnylam Pharmaceuticals, David Pirman, Senior Vice President and Head of Discovery, Biohaven, Jeremy Sokolove, Chief Medical Officer, Vor Biopharma, Dina Schneider, Vice President and Head of Discovery, Cartesian Therapeutics, Gil Wolfe, Distinguished Professor, SUNY, University at Buffalo, Pushpa Narayanaswami, Professor of Clinical Neurology, Harvard Medical School, Vice-Chair, Clinical Operations, Department of Neurology, Beth Israel Deaconess Medical Center, Richard Blumberg, Professor of Medicine, Harvard Medical School Category: Conferences | Science, Health and Medicine | Pharmaceuticals Date and Time: 21st July 2026 at 9:00 am to 23rd July 2026 at 5:00 pm Venue details: Hotel AKA Back Bay, 154 Berkeley Street, Boston, Massachusetts, 02116, United States